The Target-backed mattress and bedding brand is floating at the bottom of its range, at a valuation of less than half that of its last funding round.

University of Pennsylvania-linked CNS disorder-focused drug developer Passage Bio has filed to raise up to $125m having raised $226m in funding.

The cancer therapy developer is set to raise between $140m and $160m in its initial public offering, following $226m in funding.

The GV-backed primary care membership service floated at the bottom of its range but garnered a valution of more than $1.7bn.

Revolution Medicines, based on research from University of Illinois at Urbana-Champaign, Stanford University and UC Berkeley, has filed for a $100m initial public offering.

Bertelsmann achieved an exit as the cloud services provider raised $284m in an initial public offering that reportedly valued it at about $2bn.

The Bertelsmann, UCommune and Ant Financial-backed property manager raised nearly $130m depite downsizing its initial public offering.

The Tasly and Genexine-backed drug developer floated above the mid-point of its range, in an initial public offering that could end up topping $119m.

The Xiaomi-backed, China-headquartered podcast app developer priced its shares at the bottom of their range to raise $45.1m in a US offering.

Ping An's financial technology spinoff, which also counts SoftBank Vision Fund and SBI as shareholders, has sold an additional $35.2m in shares in the offering.